Paid Clinical Trials in District of Columbia

District of Columbia has 841 paid clinical trials enrolling now across cities including Washington D.C., Georgetown and Washinton. Search by condition, age, or phase to find compensated research studies accepting participants near you.

Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 14, 2026.

Filter results

State

City

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

756 clinical trials

Get a weekly email when new trials open in Washington D.C., DC.

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

for Triple Negative Breast Neoplasms

Sites in Washington D.C. +36 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06841354·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

for Small Cell Lung Cancer

Sites in Washington D.C. +25 more locations

Sponsor: Puma Biotechnology, Inc.

Sex: All·Age: 18+

Code: NCT06095505·Phase 2·Recruiting·Listed Oct 2023

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

for Chronic Lymphocytic Leukemia

Sites in Washington D.C. +46 more locations

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06973187·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

for Endometrial Cancer

Sites in Washington D.C. +46 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT06952504·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

for COVID-19 SARS-CoV-2 Infection

Sites in Washington D.C. +82 more locations

Sponsor: Pfizer

Sex: All·Age: 12+

Code: NCT06679140·Phase 3·Recruiting·Listed Nov 2024

Apply to this trial

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

for Lumbar Spinal Stenosis

Sites in Washington D.C. +2387 more locations

Sponsor: Stryker Instruments

Sex: All·Age: 18+

Code: NCT03072927·Recruiting·Listed Mar 2017

Apply to this trial

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

for Agitation

Sites in Washington D.C. +46 more locations

Sponsor: Celgene

Sex: All·Age: 55 - 90

Code: NCT06808984·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

for COVID-19 Infection

Sites in Washington D.C. +65 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07013474·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

for Breast Cancer

Sites in Washington D.C. +48 more locations

Sponsor: Greenwich LifeSciences, Inc.

Sex: All·Age: 18 - 100

Code: NCT05232916·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

for Migraine

Drug: Rimegepant

Sites in Washington D.C. +30 more locations

Sponsor: Pfizer

Sex: All·Age: 6 - 17

Code: NCT05156398·Phase 3·Recruiting·Listed Dec 2021

Apply to this trial

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

for Hypertension

Sites in Washington D.C. +55 more locations

Sponsor: Orchestra BioMed, Inc

Sex: All·Age: 18+

Code: NCT06059638·Recruiting·Listed Sep 2023

Apply to this trial

Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

for Refractory Angina

Sites in Washington D.C. +65 more locations

Sponsor: Shockwave Medical, Inc.

Sex: All·Age: 18+

Code: NCT05102019·Recruiting·Listed Nov 2021

Apply to this trial

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

for Obstructive Hypertrophic Cardiomyopathy

Drug: Mavacamten

Sites in Washington D.C. +47 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT05489705·Recruiting·Listed Aug 2022

Apply to this trial

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

for Cachexia

Drug: ponsegromab

Sites in Washington D.C. +82 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06989437·Phase 2, Phase 3·Recruiting·Listed May 2025

Apply to this trial

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

for Pancreatic Neuroendocrine Tumor (pNET)

Sites in Washington D.C. +39 more locations

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT06943755·Phase 2, Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

for Non-small Cell Lung Cancer

Drug: Intismeran autogene

Sites in Washington D.C. +57 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06077760·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

for Pancreatic Ductal Adenocarcinoma

Sites in Washington D.C. +24 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06586515·Phase 1·Recruiting·Listed Sep 2024

Apply to this trial

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

for Non-Small Cell Lung Cancer

Drug: sigvotatug vedotin

Sites in Washington D.C. +74 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06758401·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

for Intermediate Risk Non-Muscle Invasive Bladder Cancer

Drug: Nadofaragene Firadenovec

Sites in Washington D.C. +49 more locations

Sponsor: Ferring Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06510374·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

for Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)

Drug: Rituximab

Sites in Washington D.C. +19 more locations

Sponsor: Pierre Fabre Medicament

Sex: All·Age: All ages

Code: NCT03394365·Phase 3·Recruiting·Listed Jan 2018

Apply to this trial

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

for Peripheral Vascular Diseases

Sites in Washington D.C. +37 more locations

Sponsor: Boston Scientific Corporation

Sex: All·Age: 18+

Code: NCT04674969·Recruiting·Listed Dec 2020

Apply to this trial

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

for Ovarian Cancer

Drug: INCB123667

Sites in Washington D.C. +37 more locations

Sponsor: Incyte Corporation

Sex: Female·Age: 18 - 99

Code: NCT07023627·Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

for Carcinoma, Non-small-Cell Lung

Drug: Amivantamab

Sites in Washington D.C. +13 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05498428·Phase 2·Recruiting·Listed Aug 2022

Apply to this trial

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

for Prostate Cancer

Sites in Washington D.C. +49 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: Male·Age: 18+

Code: NCT06925737·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

for Locally Advanced Pancreatic Cancer

Sites in Washington D.C. +14 more locations

Sponsor: RenovoRx

Sex: All·Age: 18+

Code: NCT03257033·Phase 3·Recruiting·Listed Aug 2017

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

for Secondary Progressive Multiple Sclerosis (SPMS)

Drug: Remibrutinib

Sites in Washington D.C. +34 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 65

Code: NCT07225504·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

for Venous Thromboembolism

Sites in Washington D.C. +32 more locations

Sponsor: Inari Medical

Sex: All·Age: 18+

Code: NCT05701917·Recruiting·Listed Jan 2023

Apply to this trial

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

for Mitral Valve Regurgitation

Sites in Washington D.C. +66 more locations

Sponsor: Medtronic Cardiovascular

Sex: All·Age: 18+

Code: NCT03242642·Recruiting·Listed Aug 2017

Apply to this trial

FOG-001 in Locally Advanced or Metastatic Solid Tumors

for Cancer

Sites in Washington D.C. +29 more locations

Sponsor: Parabilis Medicines, Inc.

Sex: All·Age: 18+

Code: NCT05919264·Phase 1, Phase 2·Recruiting·Listed Jun 2023

Apply to this trial

JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

for AAA

Sites in Washington D.C. +24 more locations

Sponsor: Endologix

Sex: All·Age: 21+

Code: NCT05064540·Recruiting·Listed Oct 2021

Apply to this trial

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

for Alzheimer's Disease

Drug: KarXT

Sites in Washington D.C. +24 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 60 - 85

Code: NCT06976216·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

for Urothelial Cancer

Sites in Washington D.C. +32 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07106762·Phase 2, Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

for Diabetic Peripheral Neuropathic Pain

Sites in Washington D.C. +58 more locations

Sponsor: Vertex Pharmaceuticals Incorporated

Sex: All·Age: 18 - 80

Code: NCT06628908·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

for Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer

Drug: zolbetuximab

Sites in Washington D.C. +36 more locations

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All·Age: 18+

Code: NCT06901531·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

for Relapsed Non-Hodgkin Lymphoma

Sites in Washington D.C. +31 more locations

Sponsor: Lyell Immunopharma, Inc.

Sex: All·Age: 18+

Code: NCT05826535·Phase 1, Phase 2·Recruiting·Listed Apr 2023

Apply to this trial

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

for Advanced Solid Tumor

Sites in Washington D.C. +23 more locations

Sponsor: Synthekine

Sex: All·Age: 18+

Code: NCT05098132·Phase 1, Phase 2·Recruiting·Listed Oct 2021

Apply to this trial

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

for Type 2 Diabetes

Drug: Dulaglutide

Sites in Washington D.C. +40 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 10 - 17

Code: NCT06739122·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

for Upper Urinary Tract Urothelial Carcinoma

Sites in Washington D.C. +30 more locations

Sponsor: UroGen Pharma Ltd.

Sex: All·Age: 18+

Code: NCT06774131·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

A Study of ASP3082 in Adults With Advanced Solid Tumors

for Solid Tumor

Sites in Washington D.C. +24 more locations

Sponsor: Astellas Pharma Inc

Sex: All·Age: 18+

Code: NCT05382559·Phase 1·Recruiting·Listed May 2022

Apply to this trial

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

for Amyloidosis

Drug: Acoramidis

Sites in Washington D.C. +39 more locations

Sponsor: Eidos Therapeutics, a BridgeBio company

Sex: All·Age: 18 - 75

Code: NCT06563895·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial